Nov 13, 2025
Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
Nov 03, 2025
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
Oct 29, 2025
Immutep Quarterly Activities Report Q1 FY26
Oct 20, 2025
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
